{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for beta root_modifications_structuralModifications_molecularFragment_refPname in root_modifications_structuralModifications_molecularFragment_refPname (approximate match)
Status:
US Approved Rx
(2016)
First approved in 2016
Class:
PROTEIN
Status:
US Approved Rx
(2016)
First approved in 2014
Class:
PROTEIN
Status:
US Approved Rx
(2013)
First approved in 2013
Class:
PROTEIN
Status:
US Approved Rx
(2013)
First approved in 2013
Class:
PROTEIN
Status:
US Approved Rx
(2008)
First approved in 1999
Class:
PROTEIN
Status:
US Approved Rx
(1997)
First approved in 1997
Class:
PROTEIN
Status:
Investigational
Source:
NCT01097096: Phase 2 Interventional Completed Alzheimer's Disease
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01439971: Phase 1 Interventional Completed Hemophilia A
(2011)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00951405: Phase 2 Interventional Completed Congenital Bleeding Disorder
(2009)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01392547: Phase 3 Interventional Completed Congenital Bleeding Disorder
(2011)
Source URL:
Class:
PROTEIN
